M.B.A., University of California, Berkeley; B.S., international political economy, Georgetown University
Summary of Experience
Ms. Rose specializes in market access and commercial strategy projects for life sciences clients. Her experience includes market assessment in the United States and EU, evidence generation strategy and value proposition development, pricing and reimbursement evaluation, and activities to support reimbursement objectives at product launch. Most recently, Ms. Rose led the development of several global and Academy of Managed Care Pharmacy (AMCP) formulary dossiers, as well as health economic models to support new product launches. Other notable engagements include stakeholder research, including payer advisory boards and interviews, assessment of payer evidence requirements in key global markets, and forecast modeling. Her work spans diverse therapeutic areas, including oncology, infectious diseases, and rare diseases. Prior to joining Analysis Group, Ms. Rose held market planning and business development roles at Genentech and Tobira Therapeutics, and worked as an economic litigation consultant.
Budget impact of everolimus for the treatment of progressive, well-differentiated, non-functional neuroendocrine tumors of gastrointestinal or lung origin that are advanced or metastatic
Journal of Medical Economics. Apr 2017;20(4):395-404
August 18, 2016